acitretin / Generic mfg. - LARVOL DELTA

GLP-1 agonist as an adjunct therapy in benign familial chronic pemphigus (Hailey–Hailey disease) (EADV 2026) - "With no definitive cure, treatments include topicals agents (e.g. corticosteroid, antibiotics, 5-fluorouracil, …) and systemic treatments (retinoids, immunosuppressive/immunomodulating drugs, antibiotics, …) as well as laser therapy, photodynamic therapy and surgical treatments...Over the disease course the patient underwent multiple treatments including oral prednisolone, dapsone, methotrexate, adalimumab, omalizumab, apremilast, acitretin, doxycycline, low-dose naltrexone as well as UV-B therapy; however, these therapies were either ineffective or resulted in adverse effects that necessitated discontinuation...As shown in a previous report of a successful treated patient with HDD receiving liraglutide, the decrease of the proinflammatory cytokine IL-6 due to GLP-1 agonists, which has been shown to play an important role in the regulation of ATP2C1 expression in the skin, might have a causal and beneficial effect of the disease...Additionally, GLP-1 agonists, such as..."

Diabetes • Genetic Disorders • Infectious Disease • Inflammation • Metabolic Disorders • Pruritus • Type 2 Diabetes Mellitus • IL6

Targeting Type 2 Inflammation in Darier Disease: Objective Clinical Response to Dupilumab in a Retinoid-Refractory Case (EADV 2026) - "Acitretin 25 mg/day was initiated; after six months no clinical benefit was observed and treatment was discontinued due to hypercholesterolaemia (total cholesterol 244 mg/dL, LDL 159 mg/dL, triglycerides 169 mg/dL), elevated creatine kinase (292 U/L; reference ≤171 U/L), and back pain. The response to IL-4/IL-13 blockade supports the role of type 2 inflammation in DD pathogenesis and is consistent with emerging case series data. Dupilumab may represent a valuable therapeutic option in severe or retinoid-refractory DD; prospective controlled studies with standardised outcome measures are warranted."

Clinical • Atopic Dermatitis • Back Pain • Cardiovascular • Chronic Obstructive Pulmonary Disease • Dermatitis • Dyslipidemia • Hypertension • Inflammation • Musculoskeletal Diseases • Musculoskeletal Pain • Ophthalmology • Pruritus • Respiratory Diseases • IL13 • IL4

Targeted therapies in refractory lichen amyloidosis: a case report and literature review (EADV 2026) - "Previous treatments included high-potency topical corticosteroids, narrowband UVB phototherapy, isotretinoin, and acitretin, with insufficient or only transient responses...Dupilumab consistently induced rapid and sustained responses, while Janus kinase (JAK) inhibitors (baricitinib, upadacitinib, abrocitinib) demonstrated similarly robust efficacy, in some cases with faster onset...Conclusions LA should be reconsidered as a pruritus-driven inflammatory disorder with a central role for immune-mediated pathways. Targeted therapies, including biologics and JAK inhibitors, represent effective options for refractory disease and may contribute to redefining both the pathogenic framework and therapeutic approach to LA."

Case report • Clinical • Review • Amyloidosis • Atopic Dermatitis • Cardiovascular • Dermatitis • Hematological Malignancies • Hypertension • Immunology • Inflammation • Monoclonal Gammopathy • Mood Disorders • Pruritus • IL13

Association of Cutaneous and Systemic Comorbidities in Patients with Mycosis Fungoides: A Case–Control Study (EADV 2026) - "No cases of striae or acanthosis nigricans were observed in the acitretin group...These findings suggest a possible role of chronic inflammation and follicular dysfunction in the development of specific skin comorbidities. Larger, multicenter studies are needed to clarify these associations."

Clinical • Alopecia • Cutaneous T-cell Lymphoma • Dermatitis • Dermatology • Immunology • Mycosis Fungoides • Oncology • Seborrheic Dermatitis

The aggressive nature of cutaneous squamous cell cancer in solid organ transplant patients; optomising skin surveillance and management (EADV 2026) - "Topical prevention of pre-cancerous lesions was commonly used 11/12 patients were given a course of topical 5-Flurouracil (Efudix) and 8/12 had cryotherapy...There was no modification of immunosuppression with all patients remaining on their normal medications (mycophenolate mofetil (MMF) + tacrolimus 7/12; tacrolimus and prednisolone 2/12; azathioprine 1/12; and MMF 2/12)...Azathioprine is well-known for its association with UV-A photosensitivity, which has been shown to reverse after switching to MMF. Optimal management should include starting systemic agents such as acitretin and multidisciplinary co-ordination with transplant physicians to consider modification of immunosuppressive therapy."

Clinical • Basal Cell Carcinoma • Congestive Heart Failure • Genetic Disorders • Heart Failure • Infectious Disease • Melanoma • Non-melanoma Skin Cancer • Oncology • Septic Shock • Solid Organ Transplantation • Squamous Cell Carcinoma • Squamous Cell Skin Cancer • Transplantation

Clinical Characteristics, Comorbidities, Laboratory Findings, and Treatment Responses in Patients with AcquiredPerforating Dermatoses: A Retrospective Descriptive Study (EADV 2026) - "Acitretin was used in 5 patients (13.9%), antihistamines in 4 (11.1%), systemic isotretinoin in 3 (8.3%), and tetracycline in 2 (5.6%). In contrast, phototherapy demonstrated the highest descriptive response rate among evaluated treatments, suggesting that it may represent a valuable therapeutic option in selected patients. The relatively low ferritin levels observed in this cohort may warrant further investigation, particularly in relation to pruritus and treatment response."

Retrospective data • Cardiovascular • Chronic Kidney Disease • Dermatology • Diabetes • Diabetic Nephropathy • Dyslipidemia • Heart Failure • Hematological Malignancies • Hypertension • Immunology • Metabolic Disorders • Nephrology • Pruritus • Renal Cell Carcinoma • Renal Disease • Systemic Inflammatory Response Syndrome • CRP

Mycosis Fungoides: Epidemiological, Clinicopathological, Therapeutic, and Prognostic Features in a 16-Year Retrospective Study (EADV 2026) - "In early-stage disease, complete remission rates were 59% with topical corticosteroids, 66.7% with UVA phototherapy, 72.2% with narrowband UVB, 66.7% with acitretin, 60% with methotrexate, and 100% with combined acitretin-phototherapy therapy. Conclusions MF demonstrates marked clinicopathological heterogeneity and remains a therapeutic challenge. This study highlights the epidemiological and clinicopathological characteristics of MF in our region and identifies several prognostic factors associated with disease progression, which may help optimize risk stratification and therapeutic management."

Retrospective data • Cutaneous T-cell Lymphoma • Dermatology • Dermatopathology • Mycosis Fungoides • Oncology • Pruritus

Active Prevention of Keratinocyte Carcinomas in Europe: Therapeutic Choices and Decision-Making Rationales (EADV 2026) - "While consensus-based guidelines for active chemoprevention exist (recommending modalities like oral acitretin, nicotinamide, and photodynamic therapy), their real-world adoption and the rationales driving European dermatologists' therapeutic choices remain largely unclear...Topical imiquimod emerged as the most popular preventive method, significantly outpacing guideline-endorsed systemic options...A widespread preference for topical field therapies over systemic agents highlights a prevalent "systemic therapy hesitancy". To optimize healthcare resources and effectively change clinical behaviour efforts must go beyond raising awareness; they must focus on revising educational curricula, improving drug accessibility, and clarifying labelling regulations."

Non-melanoma Skin Cancer • Oncology

Succesful dupilumab treatment of prurigo nodulatis in a patient with pityriasis rubra pilaris (EADV 2026) - "Eventually, improvement was achieved using acitretin. Remission of both types of skin lesions was achieved. Conclusion The coexistence of prurigo nodularis and pityriasis rubra pilaris may present a diagnostic and therapeutic dilemma, particularly in patients with multiple comorbidities."

Clinical • Dermatology • Dermatopathology • Immunology • Prurigo Nodularis • Pruritus

One Stone, Two Birds: Successful Treatment of Generalized Granuloma Annulare and Urticarial Vasculitis with Dupilumab (EADV 2026) - "Her medical history included goiter and cardiac arrhythmia, treated with levothyroxine, bisoprolol, propafenone, and aspirin...She had received systemic corticosteroids, methotrexate, hydroxicholoroquin and azathioprine; each for at least 3 months at different time points...Multiple treatments, including intralesional and systemic corticosteroids, narrowband UVB phototherapy with acitretin, omalizumab, and cyclosporine, were ineffective...(D) Conclusion Dupilumab demonstrated efficacy and safety in the management of generalized GA and urticarial vasculitis. To our knowledge, this is the first reported case of dupilumab successfully used in both conditions."

Cardiovascular • Dermatology • Endocrine Disorders • Immunology • Rare Diseases • Urticaria • Vasculitis • CD68

Bimekizumab for Refractory Darier Disease: Targeting the IL-17 Axis in a Challenging Genodermatosis (EADV 2026) - "The disease had been present since adolescence and was refractory to multiple treatments, including long-term cyclosporine (intermittently over 4 years), systemic isotretinoin (8 months), and acitretin (25 mg/day for 4 months), all without clinical improvement and with progressive worsening of symptoms. In the present case, acitretin was planned to be discontinued due to lack of efficacy and concerns related to its use in a woman of childbearing age, prompting the search for alternative therapeutic options. Bimekizumab may represent a promising therapeutic option in refractory DD, particularly in patients unresponsive to conventional systemic therapies; however, further studies are needed to establish its long-term efficacy and safety."

Dermatology • IL17A

Severe Scalp Psoriasis Exacerbation with Alopecia During Bimekizumab Therapy: A Diagnostic Dilemma (EADV 2026) - "Her previous psoriasis treatment had included topical corticosteroids and systemic therapy with acitretin and methotrexate...Given these findings, empirical treatment with oral itraconazole and topical betamethasone/calcipotriol was initiated...Such overlapping mechanisms underscore the need for a comprehensive diagnostic approach integrating clinical, trichoscopic, histopathological, and laboratory evaluation. When a paradoxical reaction cannot be excluded, an interclass switch to an IL-23 inhibitor offers a mechanistically rational option that can achieve complete clearance and hair regrowth."

Alopecia • Dermatitis • Dermatology • Immunology • Infectious Disease • Inflammation • Plaque Psoriasis • Pruritus • Psoriasis • Seborrheic Dermatitis • IL17A • IL23A

Chronic cutaneous Lupus Erythematosus (discoid) associated with ustekinumab therapy in a patient with severe plaque psoriasis (EADV 2026) - "She developed therapeutic failure after two years of methotrexate use, associated with drug-induced hepatotoxicity. Acitretin and cyclosporine were contraindicated due to childbearing potential and residence in a tuberculosis-endemic area, respectively...Treatment with hydroxychloroquine was initiated; however, the patient developed severe drug eruption with target lesions and mucosal involvement, requiring discontinuation of the medication and initiation of systemic corticosteroid therapy with prednisone, which resulted in worsening of the previously controlled psoriasis. Due to the need to discontinue ustekinumab, therapeutic substitution with secukinumab was chosen, using an induction regimen followed by continuous maintenance therapy...In addition, it reinforces the relevance of documenting and analyzing case reports related to adverse events associated with novel biologic therapies. In this context, switching to anti-IL-17 therapy proved to be a viable and effective..."

Clinical • Cutaneous Lupus Erythematosus • Dermatology • Discoid Lupus Erythematosus • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Plaque Psoriasis • Psoriasis • Respiratory Diseases • Tuberculosis • IL17A

From Refractory Disease to Remission: Anifrolumab in Severe Discoid Lupus and Lupus Panniculitis (EADV 2026) - "Her treatment included hydroxychloroquine (200 mg daily), acitretin (25 mg daily), belimumab (from December 2021 to June 2025), low-dose aspirin, as well as topical corticosteroids and immunomodulators. She had also required multiple courses of systemic prednisone...Conclusion This case illustrates the successful use of anifrolumab in a patient with refractory cutaneous lupus, including severe discoid lupus erythematosus and lupus panniculitis, who had failed multiple systemic therapies such as acitretin and belimumab. Targeting the type I interferon pathway may represent an effective therapeutic strategy in recalcitrant cutaneous lupus, supporting the need for further studies to define its role in this subset of patients."

Clinical • Discoid Lupus Erythematosus • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Musculoskeletal Pain • Systemic Lupus Erythematosus • IFNAR2

Efficacy and safety of vunakizumab in the treatment of non-common subtypes of psoriasis: A case report of three Patients (EADV 2026) - "These patients frequently exhibit inadequate responses, high relapse rates, or poor tolerability to traditional systemic therapies (e.g., cyclosporine, acitretin), representing a significant unmet clinical need. DLQI scores decreased significantly: in the EP patient from 13 to 1, in the GPP patient from 11 to 1, and in the PPP patient from 11 to 2 at Week 12. Keywords : erythrodermic psoriasis; generalized pustular psoriasis; palmoplantar pustulosis; vunakizumab; interleukin-17A"

Case report • Clinical • Dermatology • Immunology • Inflammation • Plaque Psoriasis • Psoriasis • Pustular Psoriasis • IL17A

EPSTEIN–BARR VIRUS REACTIVATION IN A CHILD WITH GENERALIZED PUSTULAR PSORIASIS TREATED WITH SECUKINUMAB (EADV 2026) - "Initial treatment with acitretin and methotrexate was insufficient, leading to the introduction of secukinumab with rapid clinical improvement...Subsequently, the patient developed acute generalized exanthematous pustulosis induced by amoxicillin–clavulanic acid, confirmed by histopathology and pharmacovigilance assessment...This case highlights the necessity of careful monitoring and prior viral screening in children treated with secukinumab. It also demonstrates that biological therapy can be safely reintroduced after managing intercurrent complications, provided there is rigorous multidisciplinary follow-up."

Clinical • Dermatology • Dermatopathology • Endocrine Disorders • Epstein-Barr Virus Infections • Immunology • Inflammation • Plaque Psoriasis • Psoriasis • Pustular Psoriasis • Rare Diseases • IL17A

vPsoriasis or ichthyosis? About two clinical cases raising a diagnostic challenge (EADV 2026) - "Treatment with acitretin (Soriatane®) led to an initial improvement followed by relapse after discontinuation, without complete remission, and secondary development of scaly axillary lesions...An initial skin biopsy favored psoriasis, and treatment with cyclosporine was initiated without improvement...Conclusion In any diffuse erythematous-squamous dermatosis with early onset, especially in cases of consanguinity or positive family history, ichthyosis should be systematically considered. A multidisciplinary approach involving dermatology, pathology, and genetics is essential to avoid diagnostic and therapeutic errors."

Clinical • Atopic Dermatitis • Cardiomyopathy • Cardiovascular • Dermatology • Dermatopathology • Immunology • Psoriasis • Vitiligo

When hyperpigmentation is not melasma — lichen planus pigmentosus in clinical practice (EADV 2026) - "The patient was treated with systemic acitretin (25 mg once daily), topical mometasone furoate once daily, emollients, and strict photoprotection. LPP is a chronic disease affecting the junction between the epidermis and the dermis, in which the key issue is not the pigmentation itself, but a persistent, minimally symptomatic inflammatory process that damages the basal layer of the epidermis, leading to irreversible migration of pigment into the dermis. Treatment aims to suppress disease activity and stabilize the process, rather than to rapidly remove hyperpigmentation, which often persists despite control of the inflammation."

Clinical • Dermatitis • Dermatology • Dermatopathology • Immunology • Inflammation • Lichen Planus • Pruritus

Combination Therapy With Biologics and JAK Inhibitors in Refractory Psoriasis and Psoriatic Arthritis: A Cohort Study of Eight Patients (EADV 2026) - "Prior failed systemic therapies ranged from 1 to 9 per patient and included, across the cohort, anti-TNF, anti-IL-17, anti-IL-23, anti-IL-12/23 biologics, methotrexate, cyclosporine, leflunomide, acitretin, and oral JAK inhibitors used as monotherapy. The complementary mechanisms between these therapeutic classes may result in improved disease control across both tissue compartments. As one of the first reports from a Latin American cohort, this study contributes with evidence to an area where randomised trial data remain absent, and underscores the need for prospective studies to define optimal drug class pairings, sequencing and long-term safety."

Clinical • Combination therapy • Cardiovascular • Dermatology • Immunology • Infectious Disease • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL12A • IL17A • IL23A

Beyond conventional therapies: successful TYK2 inhibition in refractory lichen planopilaris (EADV 2026) - "Subsequently, oral acitretin was introduced for several months but had to be discontinued because of poor efficacy and disabling palmar xerosis...Conventional therapies, including corticosteroids, hydroxychloroquine, retinoids, tetracyclines, methotrexate, cyclosporine, and mycophenolate mofetil, often provide only partial or transient disease control, with frequent relapses after treatment withdrawal...Promising results have recently been reported with JAK inhibitors in refractory LPP, particularly tofacitinib and baricitinib...In our patient, selective TYK2 inhibition with deucravacitinib led to marked reduction of inflammatory activity and substantial hair regrowth within 9 months, with favorable clinical and biological tolerance. Thus, this case suggests a promising therapeutic approach in refractory LPP and further supports the emerging role of targeted immunomodulation in cicatricial alopecias."

Alopecia • Immunology • Inflammation • Lichen Planus • Pruritus • IL12A • IL23A • TYK2

A Unique Blend of Alopecia Areata And Monilethrix Concurrently Presenting In A Child: Trichoscopy's Revelation (EADV 2026) - "Patient was started on topical minoxidil and oral tofacitinib 2.5mg twice daily...Monilethrix has been treated successfully with topical minoxidil and oral retinoids (acitretin)...To the best of our knowledge no case has yet been reported in literature. Our case exemplifies the significance of thorough clinical examination and underscores the clinical value of trichoscopy in diagnosing concurrent hair disorders."

Clinical • Alopecia • Immunology

Refractory Palmoplantar Psoriasis Successfully Treated With Apremilast After Failure of Multiple Systemic and Biologic Therapies – A Case Report (EADV 2026) - "Previous treatment with methotrexate, acitretin, and cyclosporine had been discontinued due to adverse effects and poor tolerability...The patient subsequently underwent biologic therapy with ixekizumab followed by risankizumab; however, both treatments failed to achieve satisfactory clinical improvement...Failure of sequential biologic therapies does not preclude clinical response to phosphodiesterase-4 inhibition. Our case highlights apremilast as a potentially effective and well-tolerated therapeutic option in difficult-to-treat palmoplantar psoriasis, particularly in patients with inadequate response or intolerance to conventional systemic and biologic therapies."

Case report • Clinical • Dermatology • Immunology • Inflammation • Plaque Psoriasis • Psoriasis

Selective TYK2 Inhibition in Plaque Psoriasis: A Systematic Review of Deucravacitinib with Clinical Perspective (EADV 2026) - "In India, conventional systemic agents such as methotrexate, cyclosporine, and acitretin continue to be widely used; however, their long-term use is constrained by organ toxicity, laboratory monitoring burden, and tolerability issues...The phase 3 POETYK PSO-1 and PSO-2 trials demonstrated significantly greater efficacy of deucravacitinib versus placebo and apremilast in moderate-to-severe plaque psoriasis, with higher PASI 75, PASI 90, and sPGA 0/1 response rates at Weeks 16 and 52...Its selective allosteric inhibition of TYK2, robust efficacy, durable long-term responses, and favorable safety profile distinguish it from conventional JAK inhibitors and other oral systemic therapies. In resource-constrained settings, deucravacitinib has the potential to bridge an important therapeutic gap between traditional systemic agents and biologics, although broader accessibility, cost-effectiveness, and real-world evidence will determine its future role in routine clinical practice."

Clinical • Review • Cardiovascular • Dermatology • Hematological Disorders • Immunology • Infectious Disease • Plaque Psoriasis • Psoriasis • Respiratory Diseases • Venous Thromboembolism • IL12A • IL17A • IL23A • JAK1 • TNFA • TYK2

Psoriatic Scarring Alopecia in a Pediatric Patient: A Rare Manifestation of a Common Dermatosis (EADV 2026) - "During this period, she was treated with topical clobetasol 0.05% cream and petrolatum for palmoplantar fissures, with intermittent periods of adequate and inadequate disease control. At the age of 11, due to worsening dermatological symptoms and absence of articular involvement, oral acitretin (10 mg/day) was initiated and combined with topical therapy, resulting in good clinical response...A diagnosis of psoriatic scarring alopecia was established, and the patient was treated with adalimumab, achieving stabilization of both cutaneous and hair findings six months after therapy initiation...This case highlights the importance of careful evaluation of patients with psoriasis, particularly those with scalp involvement, as psoriatic scarring alopecia is a potentially irreversible condition. Early diagnosis is crucial to prevent unfavorable outcomes."

Clinical • Alopecia • Dermatology • Fibrosis • Immunology • Inflammatory Arthritis • Lichen Planus • Lupus • Pediatrics • Pruritus • Psoriasis • IL33

Efficacy and Acceptability of Deucravacitinib in Moderate-to-Severe Psoriasis with Comorbidities Resistant to Conventional Therapy: A Real-World Study (EADV 2026) - "All patients had previously received multiple conventional therapies, most commonly topical corticosteroids, vitamin D analogues, methotrexate, and acitretin. These findings support the role of deucravacitinib as a viable oral therapeutic option in complex psoriasis populations. Longitudinal studies with serial PASI assessments are warranted to further quantify clinical efficacy."

Clinical • Real-world • Real-world evidence • Cardiovascular • CNS Disorders • Depression • Dermatology • Diabetes • Immunology • Infectious Disease • Inflammatory Arthritis • Metabolic Disorders • Mood Disorders • Psoriasis • Psoriatic Arthritis • Respiratory Diseases • Seronegative Spondyloarthropathies • TYK2